Neurocrine Biosciences: NBI-921352
Kayak Study
TCSF is thrilled to announce that Neurocrine Biosciences' SCN8A study is now enrolling.
This is a study to evaluate NBI-921352 as adjunctive therapy in subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) in patients age 2-21. This is the first SCN8A specific clinical trial and is a huge step forward for our community!
Sept 2022–Watch our Clinical Trial Readiness series webinar with Neurocrine to get an update on this study!
Sept 2022–Watch our Clinical Trial Readiness series webinar with Neurocrine to get an update on this study!
|
SENTINEL COHORT:
The DEE2012 “KAYAK” study will enroll in two parts: a Sentinel Cohort of 8 participants and a Main Cohort of up to 52 participants. There will be a pause in participants screening and enrollment for data analysis by an independent data monitoring committee (DMC) and any needed protocol amendments following the full enrollment of the Sentinel Cohort. |
To learn more about this study, you or your doctor may contact the study research staff:
Neurocrine Medical Information Call Center 877-641-3461 medinfo@neurocrine.com ClinicalTrials.gov identifier (NCT number): NCT04873869 |
Trial Sites
(Currently USA only, international enrollment anticipated in 2023)
|
Recruiting
|
Not Yet Recruiting
|
|
Past Annual Reports
Past PCDH19 Efforts Privacy Policy The Cute Syndrome Foundation PO Box 842 Ozark, MO 65721 |
The Cute Syndrome is registered as a tax-exempt organization under IRS section 501(c)(3).
Our tax identification number is: 46-2699066. © The Cute Syndrome Foundation, All rights reserved
|
